ストックスクリーナーアプリを入手
4.44
2.54%
0.11
プレマーケット:
4.44
前日終値:
$4.33
開ける：
$4.33
24時間の取引高:
724.39K
Relative Volume:
0.59
時価総額：
$288.87M
収益：
$297.18M
当期純損益:
$-51.64M
株価収益率:
-5.5272
EPS:
-0.8033
ネットキャッシュフロー:
$-50.72M
1週間 パフォーマンス:
+8.82%
1か月 パフォーマンス:
-11.38%
6か月 パフォーマンス:
-30.30%
1年 パフォーマンス:
-56.77%
1日の値動き範囲:
$4.32
$4.46
1週間の範囲:
$4.015
$4.46
52週間の値動き範囲:
$3.86
$12.28
Evolus Inc Stock (EOLS) Company Profile
Compare EOLS vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
4.44 | 277.81M | 297.18M | -51.64M | -50.72M | -0.8033 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-06 | ダウングレード | Needham | Buy → Hold |
| 2025-04-17 | 開始されました | BTIG Research | Buy |
| 2024-01-29 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-06-23 | 開始されました | Needham | Buy |
| 2022-05-12 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-06 | アップグレード | Mizuho | Neutral → Buy |
| 2021-04-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-02-24 | ダウングレード | Truist | Buy → Hold |
| 2020-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-02-06 | 再開されました | Mizuho | Buy |
| 2019-11-26 | 開始されました | SVB Leerink | Outperform |
| 2019-09-05 | 再開されました | Mizuho | Buy |
| 2019-06-28 | 開始されました | Wells Fargo | Market Perform |
| 2019-06-11 | 開始されました | Barclays | Underweight |
| 2019-03-20 | 開始されました | SunTrust | Buy |
| 2019-02-14 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-29 | 開始されました | Stifel | Buy |
すべてを表示
Evolus Inc (EOLS) 最新ニュース
Evolus to Report First Quarter Financial Results on May 4, 2026 - Yahoo Finance UK
Evolus, Inc. (NASDAQ:EOLS) Q4 2025 earnings call transcript - MSN
Aug Big Picture: What analysts say about Evolus Inc stockQuarterly Investment Review & AI Based Trade Execution Alerts - baoquankhu1.vn
Bank Watch: What is the earnings history of Evolus Inc2026 Reactions & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
Evolus and Oramed Pharmaceuticals Compared - National Today
Evolus boosts balance sheet with lower-cost refinancing and flexibility - MSN
How The Evolus (EOLS) Investment Story Is Shifting After Softer Guidance And Target Cuts - Yahoo Finance
Evolus (LTS:0K16) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Street Watch: Is Evolus Inc showing insider buying2026 PostEarnings & Real-Time Buy Signal Notifications - baoquankhu1.vn
EOLS Stock Price, Quote & Chart | EVOLUS INC (NASDAQ:EOLS) - ChartMill
Tech Rally: Is Evolus Inc undervalued by DCF analysisQuarterly Earnings Report & Verified Swing Trading Watchlists - baoquankhu1.vn
Winners Losers: Is Evolus Inc showing insider buying2026 EndofMonth & Breakout Confirmation Trade Signals - baoquankhu1.vn
FY2026 Earnings Forecast for Evolus Issued By HC Wainwright - MarketBeat
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference - BioSpace
Market Leaders: What analysts say about Evolus Inc stockWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Evolus Inc (EOLS) Stock Price Quote Today & Current Price Chart - Capital.com
Evolus, Inc. (NASDAQ:EOLS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Death Cross: Should you avoid Evolus Inc stock right now2026 Fed Impact & High Return Stock Watch Alerts - baoquankhu1.vn
US Market Wrap: What hedge funds are buying Evolus Inc2026 Gainers & Consistent Return Strategy Ideas - baoquankhu1.vn
Vanguard disaggregates holdings for Evolus (NASDAQ: EOLS) after internal realignment - Stock Titan
Evolus, Inc.(NasdaqGM: EOLS) dropped from S&P Pharmaceuticals Select Industry Index - marketscreener.com
Evolus (NASDAQ:EOLS) Insider David Moatazedi Sells 13,669 Shares - MarketBeat
Evolus (NASDAQ:EOLS) Insider Rui Avelar Sells 3,119 Shares - MarketBeat
Avelar Rui sells Evolus (EOLS) shares worth $14815 By Investing.com - Investing.com Canada
Evolus CEO Moatazedi sells $64929 in shares By Investing.com - Investing.com Australia
Evolus CEO Moatazedi sells $64929 in shares - Investing.com
Avelar Rui sells Evolus (EOLS) shares worth $14815 - Investing.com
Evolus (EOLS) officer tax-driven sale of 3,119 shares under 10b5-1 plan - Stock Titan
Evolus (NASDAQ: EOLS) insider sells 13,669 shares to cover taxes - Stock Titan
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock By Investing.com - Investing.com South Africa
Evolus CEO Moatazedi sells $570k in shares By Investing.com - Investing.com India
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 29,996 Shares of Stock - MarketBeat
David Moatazedi Sells 116,720 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Avelar Rui, chief medical officer at Evolus, sells $146k in EOLS stock - Investing.com Australia
Evolus CEO Moatazedi sells $570k in shares - Investing.com
Evolus (EOLS) executive sells 29,996 shares after PSU vesting - Stock Titan
(EOLS) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Dip Buying: What is the earnings history of Evolus IncMarket Sentiment Review & Safe Entry Point Identification - baoquankhu1.vn
Evolus plunges after Q2 miss, guidance cut; Needham downgrades - MSN
Jobs Data: Whats the beta of Evolus Inc stockTrade Entry Summary & Fast Momentum Entry Tips - baoquankhu1.vn
Divisadero Street Capital Management LP Makes New $2.38 Million Investment in Evolus, Inc. $EOLS - MarketBeat
Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Conference - Yahoo Finance
Evolus (NASDAQ:EOLS) Rating Lowered to "Hold" at Wall Street Zen - MarketBeat
Evolus, Inc. Files Form 8-K Announcing Executive Changes and Company Information (March 13, 2026) - Minichart
Evolus reclassifies Vikram Malik to Class II director to balance board - Investing.com
Evolus reclassifies Vikram Malik to Class II director to balance board By Investing.com - Investing.com India
Vikram Malik reclassified to Class II director at Evolus - TradingView
Evolus (EOLS) reclassifies chairman Vikram Malik to restore board balance - Stock Titan
Evolus, Inc. Announces Executive Changes, Effective March 13, 2026 - marketscreener.com
How The Narrative On Evolus (EOLS) Is Resetting After Cautious 2025 And 2026 Guidance - Yahoo Finance
Evolus Inc (EOLS) 財務データ
収益
当期純利益
現金流量
EPS
1.06%
1.05%
大文字化:
|
ボリューム (24 時間):